THERAPEUTICS INITIATIVE CONFLICT OF INTEREST GUIDELINES

All Therapeutics Initiative (TI) activities must be free from any potential for undue influence arising from the private interests of the individuals involved. The Committee will operate on the basis of "full disclosure" and the following conflict of interest procedures apply to all committee and working group members, expert reviewers and staff.

- 1. The TI must be meticulous in attempting to avoid any situation where their interests conflict, or appear to conflict, with their impartial functioning in the activities and decisions of the TI.
- 2. TI members and their immediate families shall have no direct or indirect financial interest in the company sponsoring an application or trial. Any known financial or other significant consideration received from the company must be declared in writing to the Chair. These include:
 - a) If they, or their group, are receiving a grant from the manufacturer or its direct competitors.
 - b) If they are receiving a salary from the manufacturer or its direct competitors.
 - c) If they have an equity interest (other than mutual funds) in the manufacturers' company or its direct competitors.
 - d) If they have an ongoing consultancy with the manufacturer.
 - e) If they serve on a scientific advisory committee of such a company.
 - f) If they receive payment for educational activities sponsored by the company or its direct competitors.
- 3. TI members should not realize any personal financial gain that has not been approved by the chair, as a direct or indirect result of any TI decision or TI sponsored project, including promotion of books, articles or publications. In all situations where any such apparent conflict exists the individual must inform the Chair of the Committee and abstain from any deliberations relating to the decision or project.
- 4. Confidentiality of materials or discussions: No member shall knowingly divulge any confidential information relating to specific drugs to any

person other than another member of the Therapeutics Initiative unless legally required to do so.

No member shall use the information obtained as a result of his or her appointment for personal benefit.

- 5. Patentees are advised not to make direct contact with members of the Therapeutics Initiative pertaining to T.I. matters. T.I. members contacted by a patentee respecting a drug product related to the T.I. must at first opportunity disclose the nature of the contact to the chair of the T.I.
- 6. In any situation where a real or an apparent conflict exists for a TI member, the following actions must be taken:
 - a) The conflict will be recorded in writing in the appropriate minutes.
 - b) The individual will absent himself/herself from the meeting during the deliberations on the project and will not be eligible to vote on the project decision.

THERAPEUTICS INITIATIVE CONFLICT OF INTEREST STATEMENT

Similar to disclosures required when submitting articles for publication, all members of the Therapeutics Initiative need to disclose all circumstances, which could possibly be perceived to be a conflict of interest.

Please indicate whether you have any of the following affiliations with pharmaceutical companies:

		No	Yes
1.	Ownership of stock or stock options of financial instruments (does not include mutual fund ownership)		[]
2.	Ongoing paid consultancy (current or within the last 2 years).	[]	[]
3.	Employment (current or within the last 2 years).	[]	[]
4.	Honorarium or other compensation for writing a publication or for participating development of a publication	in the	[]
5.	Grant, honorarium or other compensation conducting research .	on for []	[]
6.	Speaker fees and/or educational gran (current or within the last 2 years).	<u>its</u> []	[]
7.	<u>Travel assistance</u> to attend meetings (current or within the last 2 years).	[]	[]
8.	Any <u>other</u> financial relationship which cobe perceived to be a conflict of interest. • if yes, please describe:	ould possibly []	[]
Date	Name S	ignature	